Amazing. On one hand it was n=16 and the tumors were class II and III (early stage cancers are known to respond better to immunology), but seriously, wow. >> A

Amazing. On one hand it was n=16 and the tumors were class II and III (early stage cancers are known to respond better to immunology), but seriously, wow. >> A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported. Something to look into, but oncologists tend to view progression as a time to stop and switch: >> One contributing factor might be that we administered 6 months of immunotherapy, whereas the other studies investigated shorter exposures to checkpoint blockade. Lots of interesting points in the article overall.